TransMedics Group, Inc. (TMDX)
Latest news, insights and market data
Market Data
AI Insights
No news
Latest News
| Title | Published |
|---|---|
TransMedics Group Inc. (NASDAQ:TMDX) Combines Strong Earnings Momentum with Bullish Technical Setup TransMedics Group (TMDX) combines explosive earnings growth with a strong technical setup, signaling a potential breakout for momentum investors. | about 8 hours ago |
Medical Stock Nears Buy Point Amid Liver Transplant Demand Surge Medical Stock Nears Buy Point Amid Liver Transplant Demand Surge | 1 day ago |
TransMedics Group Insider Sold Shares Worth $1,117,382, According to a Recent SEC Filing TransMedics Group Insider Sold Shares Worth $1,117,382, According to a Recent SEC Filing | 1 day ago |
Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot The mid-cap healthcare specialist is definitely worth a second look. | 6 days ago |
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results | 7 days ago |
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025. | 7 days ago |
Is It Too Late To Consider TransMedics Group (TMDX) After Its 79% One-Year Surge? Is It Too Late To Consider TransMedics Group (TMDX) After Its 79% One-Year Surge? | 8 days ago |
TransMedics Group Inc. (NASDAQ:TMDX) Combines Strong Earnings Momentum with Bullish Technical Setup
TransMedics Group (TMDX) combines explosive earnings growth with a strong technical setup, signaling a potential breakout for momentum investors.
Medical Stock Nears Buy Point Amid Liver Transplant Demand Surge
Medical Stock Nears Buy Point Amid Liver Transplant Demand Surge
TransMedics Group Insider Sold Shares Worth $1,117,382, According to a Recent SEC Filing
TransMedics Group Insider Sold Shares Worth $1,117,382, According to a Recent SEC Filing
Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot
The mid-cap healthcare specialist is definitely worth a second look.
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025.
Is It Too Late To Consider TransMedics Group (TMDX) After Its 79% One-Year Surge?
Is It Too Late To Consider TransMedics Group (TMDX) After Its 79% One-Year Surge?